Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Open-label, multicenter, single arm phase II study, set up in collaboration with the "Réseau
d'Expertise Français sur les Cancers ORL Rares" (REFCOR), evaluating the activity and safety
of single agent pazopanib in recurrent or metastatic tumors in salivary gland including
adenoid cystic carcinoma (ACC) and to exploring the activity and safety of pazopanib in
non-adenoid cystic carcinoma (non-ACC).